Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...